Hubbry Logo
TAAR5TAAR5Main
Open search
TAAR5
Community hub
TAAR5
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
TAAR5
TAAR5
TAAR5
View on Wikipedia
from Wikipedia

TAAR5
Identifiers
AliasesTAAR5, PNR, trace amine associated receptor 5, taR-5
External IDsOMIM: 607405; MGI: 2685073; HomoloGene: 20850; GeneCards: TAAR5; OMA:TAAR5 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

9038

215854

Ensembl

ENSG00000135569

ENSMUSG00000069706

UniProt

O14804

Q5QD14

RefSeq (mRNA)

NM_003967
NM_001389527

NM_001009574

RefSeq (protein)

NP_003958

NP_001009574

Location (UCSC)Chr 6: 132.59 – 132.59 MbChr 10: 23.85 – 23.85 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Trace amine-associated receptor 5 is a protein that in humans is encoded by the TAAR5 gene.[5][6][7] In vertebrates, TAAR5 is expressed in the olfactory epithelium.[8]

Human TAAR5 (hTAAR5) is a functional trace amine-associated receptor which acts as an olfactory receptor for tertiary amines.[8][9] Trimethylamine and N,N-dimethylethylamine are full agonists of hTAAR5.[9][10][11] The amber-woody fragrance timberol antagonizes this activity of trimethylamine.[12] 3-Iodothyronamine is an inverse agonist of hTAAR5.[13][14] Recent studies highlighted the significant role of TAAR5 in the central nervous system and periphery. Beta-galactosidase mapping of TAAR5 expression showed its localization not only in the glomeruli but also in deeper layers of olfactory bulb projecting to the limbic brain olfactory circuitry. Moreover, TAAR5 knockout mice show increased adult neurogenesis and elevated number of dopamine neurons. Also, it was observed statistically significant changes in osmotic erythrocyte fragility in TAAR5-KO mice.[15]

Mutations in the TAAR5 gene were found to affect human olfaction. Icelanders with a mutation in the gene were less likely to describe fish smell containing trimethylamine as unpleasant, and described licorice odor and cinnamon odor more intensely.[16]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

TAAR5

View on Grokipedia
from Grokipedia
Trace amine-associated receptor 5 (TAAR5) is a protein-coding located on chromosome 6q23.2 in humans that encodes a (GPCR) primarily involved in olfaction and . This receptor, also known as PNR or taR-5, enables (TMA) receptor activity and participates in the adenylate cyclase-activating signaling pathway, contributing to sensory detection and behavioral regulation. TAAR5 belongs to the trace amine-associated receptor family (–TAAR9), a group of nine GPCRs in humans (with six functional genes) that detect low-molecular-weight endogenous , distinct from the broader aminergic receptor families like those for or serotonin. In vertebrates, TAAR5 is predominantly expressed in the , where it functions as a specific for TMA—a volatile trace enriched in decaying and mammalian —triggering innate responses that influence social and avoidance behaviors. It is also detected in limbic brain regions, including the , hippocampus, , and , as well as the and , allowing it to modulate emotional processing, serotonin and transmission, and sensorimotor functions beyond pure olfaction. The primary endogenous ligand for TAAR5 is TMA, which acts as a full agonist at low micromolar concentrations, while it shows lower activation by related amines like dimethylethylamine; known agonists include α-NETA, and inverse agonists such as 3-iodothyronamine (T1AM), and antagonists such as Timberol have been identified through pharmacological studies. Physiologically, TAAR5 activation promotes olfactory input to limbic areas, regulating anxiety- and depression-like behaviors, adult neurogenesis, and motor coordination—evidenced by knockout mouse models exhibiting reduced anxiety, enhanced balance, but impaired endurance and muscle strength. As of November 2024, TAAR5 knockout mice also demonstrate enhanced adult neurogenesis and increased dopamine transmission in the striatum. Dysregulation of TAAR5 has been associated with conditions like trimethylaminuria (a metabolic disorder causing fish odor syndrome) and potentially broader neuropsychiatric disorders involving olfactory dysfunction, such as schizophrenia or mood disorders. Due to its role in modulating monoamine systems and emotional responses, TAAR5 has emerged as a therapeutic target for anxiety, depression, and motor-related conditions, with recent structure-based yielding novel antagonists that exhibit and potential in preclinical models. The receptor's single-exon structure and evolutionary conservation across mammals underscore its specialized niche in integrating sensory cues with functions.

Genetics

Genomic location

The human TAAR5 gene is located on the long arm of at the cytogenetic band 6q23.2. In the GRCh38.p14 assembly, it spans 28,156 base pairs from genomic position 132,588,592 to 132,616,747 on the reverse strand. The consists of 4 exons. TAAR5 forms part of a clustered family of trace amine-associated receptor on 6q23.2, which includes neighboring functional such as TAAR6 and TAAR8. The mouse ortholog, Taar5, is situated on chromosome 10 at band A4 (GRCm39 assembly, positions 23,846,604–23,847,617 on the forward strand). TAAR5 orthologs exhibit strong conservation across mammalian species, remaining intact and functional in all studied lineages from rodents to primates.

Gene structure

The human TAAR5 gene is organized into four exons spanning approximately 28 kb on chromosome 6q23.2, encoding a 340-amino acid protein characteristic of G protein-coupled receptors in the trace amine-associated receptor family. Exon 1 includes the 5' untranslated region (UTR), exon 2 contains the entire coding sequence including the start codon (ATG) and stop codon, while exons 3 and 4 contain the 3' UTR. The three introns interrupt the UTR regions, with GT-AG splice sites at the exon-intron boundaries, facilitating precise splicing in olfactory tissues where the is primarily expressed. Intron lengths vary, contributing to the compact yet regulated genomic architecture typical of genes. While the human gene has a multi-exon structure, this is not fully conserved across mammalian orthologs; for example, the Taar5 consists of a single , where similar exon arrangements support evolutionary preservation of receptor function despite variations in non-coding regions. Upstream of exon 1 lies the promoter region, which includes a CpG island and binding sites for transcription factors such as those involved in olfactory-specific regulation. Key regulatory elements encompass cooperative enhancers located within intronic and intergenic sequences, which coordinate TAAR5 expression in olfactory sensory neurons by interacting with distant loci to ensure monoallelic activation akin to other olfactory receptors. Alternative splicing of TAAR5 yields primarily a single transcript (e.g., NM_003967.3) with no major functional isoforms reported, though a minor variant (NM_001389527.1) incorporates additional exons in the UTRs without altering the core protein sequence. This limited splicing variability underscores the gene's streamlined expression for specialized sensory roles.

Protein

The human TAAR5 protein is a 337-amino-acid polypeptide with a calculated of 38,242 Da. As a member of the class A (GPCR) superfamily, TAAR5 possesses a characteristic primary structure consisting of an extracellular N-terminal domain, seven α-helical transmembrane segments (TM1–TM7), three intracellular loops (ICL1–ICL3), three extracellular loops (ECL1–ECL3), and an intracellular C-terminal tail. Notable sequence motifs include the conserved DRY triad (Arg^{3.50}-Asp^{3.51}-Tyr^{3.52}) at the cytoplasmic end of TM3, which plays a critical role in receptor activation by facilitating interactions with G proteins upon ligand binding. The ligand-binding pocket in the transmembrane core features key residues such as Asp^{3.32} in TM3, which forms a with the positively charged amine group of substrates like . TAAR5 shares approximately 39–45% amino acid sequence identity with other human TAAR family members (, TAAR2, TAAR6, TAAR8, and TAAR9), with higher conservation in the transmembrane helical regions that form the core .

Tertiary structure

TAAR5 belongs to the class A family of G protein-coupled receptors (GPCRs), characterized by a tertiary structure consisting of seven transmembrane α-helices (TM1–TM7) that form a compact bundle embedded in the . This arrangement creates a central orthosteric within the transmembrane core, flanked by extracellular and intracellular loops. The overall fold is stabilized by conserved sequence motifs, such as the NPxxY motif in TM7 and the DRY motif at the cytoplasmic end of TM3, which contribute to the structural integrity and functional dynamics of the receptor. Due to the absence of an experimentally determined atomic for TAAR5, and computational predictions have been employed to elucidate its three-dimensional architecture. Early models for TAAR5 were built using the inactive-state structures of the β1-adrenergic receptor (PDB: 2Y03) and β2-adrenergic receptor (PDB: 4GBR) as templates, with the extracellular loop 2 (ECL2) refined based on the Y1 receptor (PDB: 5ZBH). More recent AlphaFold-Multimer predictions for the TAAR5–Gq protein complex achieve high confidence, with an average predicted local distance difference test (pLDDT) score of 85.8, indicating reliable modeling of the seven-helix bundle and associated domains. These models align closely with the rhodopsin-like fold typical of receptors. The ligand-binding pocket of TAAR5 forms a hydrophobic cleft buried in the , primarily involving residues from TM3, TM6, and TM7. Key structural features include the conserved aspartate residue Asp^{3.32} (D114 in ) in TM3, which facilitates ionic interactions, alongside aromatic residues like Phe^{6.51} (F268) and Trp^{6.48} (W265) in TM6 that contribute to π-π stacking. Additional TAAR5-specific residues, such as Thr^{3.33} (T115) in TM3 and Thr^{6.52} (T269) in TM6, line the pocket, creating a selective environment for small ligands. Induced-fit docking refinements of these models yield distinct conformations with good predictive performance (ROC AUC ≈ 0.70). TAAR5 can adopt distinct conformational states corresponding to its inactive and active forms, as inferred from computational models. In the inactive state, the helices are closely packed, with TM6 in an inward position. Activation involves an outward tilt of TM6 by approximately 14 Å at its cytoplasmic end, opening the intracellular face for coupling, a mechanism conserved across class A GPCRs and captured in the complex model with . This transition is supported by simulations of homology models, which highlight rigidification of the binding pocket upon engagement.

Expression

Tissue distribution

TAAR5 is primarily expressed in the of vertebrates, including humans, mice, and rats, where it functions as an . In humans, high mRNA levels have been detected in this tissue via RNA-seq analysis. Similar strong expression patterns are observed in , with TAAR5 localized to olfactory sensory neurons in the epithelium of mice and rats. Low-level expression of TAAR5 occurs in various human brain regions, particularly limbic areas such as the , hippocampus, and , as well as the and periventricular zones like the and . These patterns were identified through (with counts per million <0.5 in positive samples) and microarray datasets showing expression in 15-47% of samples across log2-normalized intensities >5.0, alongside confirmation in mouse models. In mice, comparable low expression extends to additional limbic structures including the anterior olfactory nucleus, , and . Species differences in TAAR5 expression are notable, with exhibiting robust expression, while expression appears more restricted overall but includes the testis, where it is detected in male germ line stem cells via transcriptomic data. In s, from the Human Protein Atlas confirms low to moderate levels in testicular tissue. Low expression has also been reported in peripheral organs such as the intestines and leukocytes. Developmentally, TAAR5 expression in olfactory neurons is upregulated in adults compared to embryos, with substantial mRNA presence emerging around embryonic day 15 in rats and increasing postnatally to peak in mature sensory neurons. Minimal expression is observed in early embryonic stages prior to this onset.

Cellular localization

TAAR5, a G-protein-coupled receptor, is primarily localized to the plasma of olfactory sensory neurons (OSNs) in the main , where it functions in odor detection. Within these neurons, TAAR5 is expressed on the dendritic cilia, the site of odorant interaction, and is also present in axons projecting to the . The receptor is trafficked to the plasma membrane via the classical secretory pathway, involving synthesis in the and processing in the Golgi apparatus, as evidenced by perinuclear staining in immunohistochemical analyses of murine OSNs. In the brain, TAAR5 expression is restricted to specific neuronal populations within limbic and related structures, with no detectable expression in glial cells or other non-neuronal elements. Histological mapping using β-galactosidase reporter in TAAR5 mice reveals TAAR5-positive neurons in the , as well as in granule cells of the . Additional localization occurs in neurons of the ventromedial hypothalamic nucleus and , contributing to its role in limbic circuitry. Immunohistochemical studies confirm co-localization of β-galactosidase with neuronal markers in these regions, underscoring the receptor's neuronal specificity.

Ligands and signaling

Known ligands

TAAR5 is primarily activated by the endogenous trimethylamine (TMA), a volatile tertiary generated from the microbial degradation of such as choline-rich foods and present in . TMA serves as an for both and orthologs of TAAR5, though with species-specific potency differences; in humans, TMA exhibits an EC50 of approximately 100-120 μM, while mouse TAAR5 displays heightened sensitivity with EC50 values around 1-10 μM. Unlike primary or secondary amines such as or β-phenylethylamine, which do not activate TAAR5, TMA and related tertiary amines specifically engage the receptor. Additional agonists include N,N-dimethylethylamine (DMEA), another tertiary amine with lower potency than TMA at TAAR5 (EC50 ≈ 169 μM). In mice, α-NETA (also known as N-ethyl-N-ethoxycarbonyl-4-aminobutyrate) functions as a potent , influencing behavioral responses mediated by TAAR5. Several antagonists have been identified for TAAR5, with Timberol (a synthetic amber-woody fragrance compound) acting as a potent and selective inhibitor of TAAR5, blocking TMA-induced with high specificity among tested olfactory receptors. Computational approaches, including and , have yielded novel antagonists for mouse TAAR5, such as analogs of the antagonist EPPTB and other small molecules exhibiting sub-micromolar to low micromolar IC50 values (e.g., 1.1 μM). Recent efforts as of 2024 have identified additional novel TAAR5 antagonists, further expanding the pharmacological toolkit.

Signaling pathway

TAAR5 functions as a (GPCR) that preferentially couples to the stimulatory Gαs. binding to the orthosteric site induces a conformational change in the receptor, promoting the exchange of GDP for GTP on the Gαs subunit and subsequent dissociation of the Gαs-GTP from the Gβγ complex. The free Gαs-GTP then activates (AC), catalyzing the conversion of ATP to (cAMP), thereby elevating intracellular cAMP levels. This Gs-mediated pathway is conserved across the trace amine-associated receptor (TAAR) family, including TAAR5, as demonstrated in systems. In functional assays using HEK293-derived cells transiently transfected with human TAAR5 and a cAMP-responsive reporter, activation by the agonist (TMA) produces a concentration-dependent increase in cAMP with an EC50 of approximately 116 μM. Similar results have been observed in other mammalian TAAR5 orthologs, confirming the receptor's efficacy in transducing signals through this pathway in non-olfactory cellular contexts. The rise in cAMP activates downstream effectors, primarily (PKA), which phosphorylates target proteins to modulate cellular responses. Potential substrates include the CREB, whose at Ser133 can drive changes relevant to neuronal signaling, though specific TAAR5-mediated CREB remains under investigation. TAAR5 also induces ERK1/2 , as demonstrated in HEK293 cells expressing the receptor, though whether this occurs via β-arrestin or other pathways is undetermined. Desensitization of TAAR5 likely follows the general mechanisms observed in class A GPCRs, involving agonist-induced phosphorylation by G protein-coupled receptor kinases (GRKs) on serine and threonine residues in the intracellular loops and C-terminal tail, promoting β-arrestin recruitment, uncoupling from Gαs, and clathrin-mediated endocytosis. However, specific studies confirming this process for TAAR5 are lacking. As with other class A GPCRs, such mechanisms would prevent overstimulation and enable receptor trafficking for recycling or degradation.

Physiological roles

Olfactory function

TAAR5 functions as an primarily expressed in the , where it detects volatile amines such as (TMA), a compound associated with signals of decay in food or social cues like urine pheromones in . This detection enables the receptor to contribute to the innate sensing of environmentally relevant odors without requiring prior learning. In mice, activation of TAAR5 by TMA, present in male urine, elicits attractive behaviors that promote social interactions, mediated through projections resembling those of the vomeronasal system. In contrast, the same induces aversion in rats and humans, where TMA evokes perceptions of unpleasant fishy odors indicative of spoilage. These species-specific responses highlight TAAR5's role in modulating instinctive behavioral outputs tailored to ecological contexts. TAAR5-expressing neurons project axons to a discrete set of four to six glomeruli in the dorsal region of the , forming a specialized zone for processing. These targeted projections facilitate rapid transmission of sensory information to downstream circuits, directly influencing innate avoidance or approach behaviors independent of associative learning. As part of a dedicated -detecting subsystem, TAAR5 complements the broader array of canonical olfactory receptors (ORs) by providing high-sensitivity encoding for biogenic , thereby enriching the olfactory code for biologically salient volatiles. This subsystem ensures efficient discrimination of -based odors within the complex sensory landscape of the .

Central nervous system roles

TAAR5, expressed in key limbic brain regions such as the , hippocampus, and , as well as neurogenic zones like the subventricular and subgranular zones, plays a role in modulating emotional behaviors beyond its olfactory functions. In TAAR5 (KO) mice, reduced anxiety-like behaviors are observed across multiple paradigms, including the and open field tests, with increased time spent in open arms and enhanced exploratory activity without alterations in general locomotion. These mice also exhibit antidepressant-like effects, such as decreased immobility in the forced swim test, indicating TAAR5's involvement in regulating emotional states through central mechanisms. TAAR5 influences systems in limbic areas, particularly serotonin (5-HT) transmission and . models demonstrate decreased serotonin levels in the and hippocampus, alongside a 30% elevation in striatal and its metabolites, coupled with an increased number of neurons in the . Furthermore, is enhanced twofold in the subventricular and subgranular zones, as evidenced by higher proliferation markers like (DCX) and (PCNA), suggesting TAAR5 acts as a negative regulator of these processes to maintain in limbic circuitry. In terms of motor functions, TAAR5 contributes to coordination, balance, and postural stability, with expression noted in the and medial vestibular nucleus. TAAR5 KO mice show improved performance in balance tasks, such as faster traversal on a static rod (5.16 ± 0.59 s versus 7.19 ± 0.56 s in wild-type) and quicker recovery from vestibular perturbations (7.42 ± 0.46 s versus 11.68 ± 1.74 s), alongside fewer missteps (1.33 ± 0.27% versus 2.94 ± 0.72%) in complex ladder walking, indicating enhanced sensorimotor precision despite reduced endurance on rotarod tests. These findings link TAAR5 to fine-tuned via cerebellar and vestibular pathways. TAAR5 also impacts cognitive processes, particularly learning and error minimization. In interval-timing tasks, TAAR5 KO mice display superior overall performance with fewer timing s (p < 0.005) and timeouts (p = 0.02), achieving a higher rate of improvement over training days (p < 0.005) compared to wild-type controls, while maintaining intact impulsivity and temporal accuracy. This suggests TAAR5's suppressive role in cognitive flexibility within prefrontal-limbic networks. Recent research as of 2025 indicates that TAAR5 modulates circadian rhythms through TMA sensing; TAAR5 KO mice show altered oscillations in core circadian genes, metabolic hormones like insulin and corticosterone, and gut microbiome composition, particularly under high-fat diet conditions.

Clinical significance

Genetic variants

A low-frequency missense variant in the TAAR5 gene, p.Ser95Pro (rs41286168), has been identified through genome-wide association studies (GWAS) as influencing human odor perception. This variant is located in the coding region and alters the receptor's amino acid sequence at position 95 from serine to proline. Carriers of the p.Ser95Pro variant exhibit reduced perceived intensity of fish-like odors containing trimethylamine (TMA), with an effect size of -0.37 standard deviations (combined p = 5.6 × 10⁻¹⁵ across cohorts). This variant is also associated with increased pleasantness ratings of TMA odors (b = 0.10 SD, p = 0.021) and higher rates of TMA anosmia (OR = 2.72, p = 2.4 × 10⁻³), as well as difficulties in naming such odors (OR = 1.69, p = 5.6 × 10⁻⁸). In silico analyses predict that p.Ser95Pro is deleterious (SIFT score indicating damaging effect) and probably damaging (PolyPhen-2), suggesting impaired receptor function, though direct in vitro confirmation of altered ligand binding or signaling remains limited. Population genetic data reveal that the p.Ser95Pro variant occurs at higher frequencies in individuals of European ancestry, with a minor allele frequency (MAF) of 2.2% in Icelanders and 1.7% in Swedes, compared to 0.8% in Southern Europeans and 0.2% in African populations (based on gnomAD database). This variant lies within a GWAS locus linked to olfactory variation, highlighting TAAR5's role in inter-individual differences in odor sensitivity. Rare loss-of-function alleles in TAAR5, such as a stop-gained variant with MAF < 0.17%, have been detected but show no significant associations with altered odor sensitivity in tested cohorts (p > 0.08). No common variants in TAAR5 have been identified as strongly causal for non-olfactory disorders, underscoring its primary relevance to sensory variation.

Associated disorders

TAAR5 is the primary for (TMA). (TMAU) is a characterized by the accumulation of TMA due to impaired oxidation by (FMO3), leading to a fish-like . Specific sequence variations in TAAR5, such as p.Ser95Pro, influence individual responses to fish odor and linguistic descriptions of its unpleasantness. Altered TAAR5 expression has been observed in several neurological conditions. In (MDD), significant downregulation of TAAR5 occurs in the , potentially contributing to dysregulated emotional processing. Similarly, TAAR5 is downregulated in the of individuals with . In contrast, TAAR5 expression is upregulated in the of patients with HIV-associated , suggesting a role in neuroinflammatory responses. Furthermore, TAAR5 modulates and transmission in neurogenic zones such as the subventricular and subgranular zones, with knockout models showing a twofold increase in proliferating neurons, indicating potential involvement in neurodegenerative disorders such as through impaired neurogenesis. TAAR5 antagonists hold therapeutic promise for anxiety and depression, as evidenced by knockout mouse phenotypes exhibiting reduced anxiety-like and depressive-like behaviors alongside enhanced signaling and . Structure-based has identified novel TAAR5 antagonists, such as compounds with values in the low micromolar range (e.g., 2.8–3.5 µM), which could serve as lead candidates for developing treatments targeting limbic areas to alleviate mood disorders. As of 2025, TAAR5 is also being explored as a potential therapeutic target for . In inflammatory contexts, TAAR5 signaling promotes mucosal and in (IBD) models, as of a 2025 study. TAAR5 expression positively correlates with markers of and , such as α-smooth muscle actin (αSMA) and (TNF), in intestinal mucosal biopsies from IBD patients. Taar5 knockout mice are protected against dextran sulfate sodium (DSS)-induced , displaying reduced fibrotic responses in chronic models, highlighting TAAR5 as a potential target for anti-fibrotic therapies in IBD.

References

  1. https://www.ncbi.nlm.nih.gov/gene/9038
  2. https://www.uniprot.org/uniprotkb/O14804/entry
  3. https://www.mdpi.com/1422-0067/23/6/3127
  4. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2020.00018/full
  5. https://www.nature.com/articles/s41598-021-02289-w
  6. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0117774
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11592834/
  8. https://www.genecards.org/cgi-bin/carddisp.pl?gene=TAAR5
  9. https://pubs.acs.org/doi/10.1021/acs.jcim.3c00755
  10. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00680/full
  11. https://www.informatics.jax.org/marker/MGI:2685073
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2838891/
  13. https://www.omim.org/entry/607405
  14. https://academic.oup.com/mbe/article/24/9/2099/2925742
  15. https://www.nature.com/articles/s41467-021-23824-3
  16. https://omim.org/entry/607405
  17. https://www.nature.com/articles/s41421-025-00839-4
  18. https://elifesciences.org/articles/10441
  19. https://www.mdpi.com/1422-0067/23/1/209
  20. https://gpcrdb.org/structure/complex_models/AFM_TAAR5_HUMAN_GNAQ_HUMAN
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395715/
  22. https://www.proteinatlas.org/ENSG00000135569-TAAR5/tissue
  23. https://academic.oup.com/chemse/article/32/6/623/318188
  24. https://www.bgee.org/gene/ENSG00000135569
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC3421222/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC7066256/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3564852/
  28. https://www.jneurosci.org/content/33/7/3228
  29. https://pubmed.ncbi.nlm.nih.gov/29713997/
  30. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0144704
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC11312273/
  32. https://pdfs.semanticscholar.org/456f/12ec040afe4365e3a6b0af65ddd828154d04.pdf
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508243/
  34. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0054950
  35. https://www.cell.com/current-biology/fulltext/S0960-9822(12)01268-7
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC8954676/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC9418498/
  38. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00125/full
  39. https://pubmed.ncbi.nlm.nih.gov/16878137/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC3408605/
  41. https://doi.org/10.3389/fnmol.2020.00018
  42. https://doi.org/10.4103/1673-5374.327338
  43. https://doi.org/10.1016/j.neuropharm.2020.108373
  44. https://www.nature.com/articles/s41598-022-18924-z
  45. https://elifesciences.org/reviewed-preprints/107037
  46. https://www.cell.com/current-biology/fulltext/S0960-9822(20)31343-9
  47. https://pubmed.ncbi.nlm.nih.gov/33035477/
  48. https://doi.org/10.1021/acs.jcim.3c00755
  49. https://actaspsiquiatria.es/index.php/actas/article/view/1916
  50. https://academic.oup.com/ibdjournal/article/31/Supplement_1/S52/7978569
Add your contribution
Related Hubs
User Avatar
No comments yet.